Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/02/2005US20050119324 Moderate transcription factor; estrogen receptors; free from creatine kinase stimulation
06/02/2005US20050119323 Hormone sensitive vcancer; antiproliferative agents ; induction apoptosis; angiotensin inhibitors
06/02/2005US20050119322 Phorboxazole derivatives for treating cancer
06/02/2005US20050119321 2-substituted-1,3-thiazole compounds
06/02/2005US20050119320 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
06/02/2005US20050119319 Using 1,3-diazaspiro( 4.5)decane-2,4-(dione or dithione)
06/02/2005US20050119317 such as (5RS)-3-(3-Fluoro-4-thiomorpholin-4-yl phenyl)-5-(1,2,3-triazol-1-ylmethyl)-4,5-dihydroisoxazole; antibiotics
06/02/2005US20050119316 Semicarbazide derivatives and the use thereof as antithrombotics
06/02/2005US20050119315 Cardiovascular disorders; antiarrhythmia agents; sodium channel moderators; potassium channel moderators; prevention fibrillation
06/02/2005US20050119314 Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
06/02/2005US20050119313 Aqueous antiseptic based on bispyridiniumalkanes
06/02/2005US20050119312 Lipid lowering agents; hypotensive agents; obesity
06/02/2005US20050119310 nucleoside / nucleitide antiviral agents [2'-deoxy-3'-thiocytidine-5'-triphosphate (3TC)]; immunomodulators / immunostimulants; synergistic effect; prevent drug resistance; reduce toxicity
06/02/2005US20050119309 Compositions and methods for selective inhibition of nicotine acetylcholine receptors
06/02/2005US20050119308 Remedy for sleep disturbance
06/02/2005US20050119307 Method of treating attention deficit disorders with D-threo methylphenidate
06/02/2005US20050119306 Blocking transcription factor; culture product of transgenic fungi
06/02/2005US20050119305 N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide; hydroxamic acid derivative and equivalent thereof; antiinflammatory, anticarcinogenic, antiarthritic, antidiabetic agents; sepsis, leukemia, osteoporosis, skin disorders, cachexia, autoimmune diseases, hepatitis, endometriosis; hypergammaglobulinemia
06/02/2005US20050119304 N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(1H-indazol-5-yl)urea; vanilloid receptor (VR1) antagonist; blockage of neurotransmitter release
06/02/2005US20050119303 kit; N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide; VEGF (endothelial growth factor)and FGF (fibroblast growth factor) receptor kinase inhibitors or antibody; integrin inhibitor; synergistic
06/02/2005US20050119302 Methods for the prevention or treament of bacterial and fungal infections
06/02/2005US20050119301 Treatment of restenosis
06/02/2005US20050119300 Wound healing agents; using thalidomide- type compound
06/02/2005US20050119299 Ophthalmic solutions containing tetrazole derivatives
06/02/2005US20050119297 Use of 5HT3 agonists for relaxing the fundus
06/02/2005US20050119296 6-(1-benzofuran-2-yl)-2-(trifluoromethyl)quinolin-4-yl 1H-tetraazol-5-ylmethylether; plasminogen activator inhibitor; impairment of fibrinolytic system; cystic fibrosis, diabetes, chronic periodontitis, lymphomas; increased uPA levels (breast and ovarian cancer)
06/02/2005US20050119295 Fused heterocyclic compounds
06/02/2005US20050119294 Preparation of 1H-imidazo [4,5-c] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates
06/02/2005US20050119292 antibiotic; Gram-positive pathogens (Staphylococci, Enterococci, and Streptococci ), MRSA and MRCNS; resistance to vancomycin and E. faecium to both aminoglycosides and beta--lactams; gram negative strains H.influenzae, M.catarrhalis and chlamydia; improved activity against mono-amine oxidase (MAO)
06/02/2005US20050119291 Pyrimidine compounds
06/02/2005US20050119290 N-(2-[N',N'-diethylamino]-5-[N''-(4-fluorophenylsulfonyl)-N''-propargylamino]pyrimidin-4-yl)-4'-(pyrrolidin-1-ylcarbonyloxy)-L-phenylalanine; antiinflammatory, antiarthritic agents
06/02/2005US20050119289 Synergistic mixture; anticancer agents; therapy for skin cancer; adenosine receptor antagonist
06/02/2005US20050119288 Dosing schedule for a novel anticancer agent
06/02/2005US20050119287 8-(1-methyl-1H-pyrrol-2-yl)-1,3-dipropyl-1H-pyrrolo[3,2-d]pyrimidine-2,6-dione; asthma, chronic obstructive pulmonary disorder, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders
06/02/2005US20050119286 Beta-2'-or 3'-halonucleosides
06/02/2005US20050119285 Treatment of neurological disorders related to rapid eye movement (REM) sleep disturbances with NPY Y5 receptor antagonists
06/02/2005US20050119284 inhibitors of RNA virus replication; the flaviviruses hepatitis C virus (HCV) and bovine diarrhea virus (BVDV); ability to target glutathione rich tissues; reduced systemic toxicity so fewer side effects at higher doses; a thiopurine nucleoside analog; cis or trans-6-(2-acetylvinylthio)purine (AVTP)
06/02/2005US20050119283 Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist
06/02/2005US20050119282 Pyrazolopyrimidines and related analogs as HSP90-inhibitors
06/02/2005US20050119281 Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
06/02/2005US20050119280 1-[alkyl 1-[heteroaryl )alkyl] and 1-[ aryl) alkyl]-7-( pyrimidin-4-yl) imadazo [1,2-a] pyrimidin-5(1h)-one derivatives
06/02/2005US20050119278 Anti-angiogenesis methods
06/02/2005US20050119277 Benzazole derivatives for the treatment of scleroderma
06/02/2005US20050119276 Methods of treating inflammatory bowel disease using NF-kB inhibitors
06/02/2005US20050119275 Antiinflammatory agents; autoimmune disease; Alzheimer's disease; anticancer agents; antiarthritic agents; antidiabetic agents; lupus; interinflammatory agents
06/02/2005US20050119274 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases;
06/02/2005US20050119273 Small molecule toll-like receptor (TLR) antagonists
06/02/2005US20050119272 amplify the effect of nitric oxide on skeletal muscle insulin-mediated glucose uptake; antidiabetic agents
06/02/2005US20050119271 Pyrimidine A2B selective antagonist compounds, their synthesis and use
06/02/2005US20050119270 Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
06/02/2005US20050119269 Heterocyclic compounds and methods of making and using thereof
06/02/2005US20050119268 Treatment of CRTH2-mediated diseases and conditions
06/02/2005US20050119267 Diazabicyclo alkane derivatives with nk1 antagonistic activity
06/02/2005US20050119266 Pyrrolidine and piperidine derivatives as factor Xa inhibitors
06/02/2005US20050119265 Novel crystalline forms of lamotrigine
06/02/2005US20050119264 Tetrahydrobenzfluorene derivatives
06/02/2005US20050119263 Synergistic mixture of n,n-diethyl, (2-(4-phenylnethyl)phenoxy) ethanamine and adriamycin
06/02/2005US20050119262 Synergistic mixture for vision disorders
06/02/2005US20050119261 Analgesics; neuropathic pain; antiepileptic agents; irritable bowel syndrome; antidepressants; anxiolytic agents; multiple sclerosis; bipolar disorders
06/02/2005US20050119259 Synergistic mixture of anticoagulant and antiarrhythmia agents
06/02/2005US20050119258 Xanthines 3-and 8-substituted with an arylalkylene or heteroarylalkylene, e.g. 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine and 3-[2-(4-Aminophenyl)ethyl]-1-propyl-8-[(3-pyridyl)methyl]xanthine
06/02/2005US20050119257 Cyclic sulfone containing retroviral protease inhibitors
06/02/2005US20050119255 Phenylpyrimidine amines as ige inhibitors
06/02/2005US20050119254 Antitumor agents; using taurolidine; administering into lungs
06/02/2005US20050119253 Psychological disorders; central nervous system disorders; anxiolytic agents; using pipamperone
06/02/2005US20050119252 Ligands of melanocortin receptors and compositions and methods related thereto
06/02/2005US20050119251 Nicotinamide derivatives and their use as therapeutic agents
06/02/2005US20050119250 Amino-derivatives as novel inhibitors of histone deacetylase
06/02/2005US20050119249 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
06/02/2005US20050119248 Psychological disorders; central nervous system disorders
06/02/2005US20050119246 2-(4-{[1-(2,2-dimethylpropanoyl)-4-piperidinyl]methyl}-3,5-dimethyl-1H-pyrazol-1-yl)-1-methylethylcarbamate; appetite suppressants; obesity, diabetes, feeding behavior, bulimia, anorexia nervosa and premenstrual tension; side effect reduction
06/02/2005US20050119243 HIF-1 inhibitors and methods of use thereof
06/02/2005US20050119242 Reducing cell differentiation of adipocyte; reducing body fat
06/02/2005US20050119239 Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism
06/02/2005US20050119238 Administering acetylsalicylic acid in carrier to prevent tumors
06/02/2005US20050119237 Non-malignant disease treatment with Ras antagonists
06/02/2005US20050119236 Cancer treatments and pharmaceutical compositions therefor
06/02/2005US20050119235 7-phenyl-substituted tetracycline compounds
06/02/2005US20050119234 Cannabimimetic indole derivatives
06/02/2005US20050119232 10 alpha -(sulfamino)dihydroartemisinin and Bis[(10 alpha -dihydroartemisinyl)]sulfamide; parasiticide; malaria, neosporosis and coccidiosis; Plasmodium falciparum, Neospora caninum and Eimeria tenella; improved stability, bioavailability, neurotoxicity
06/02/2005US20050119231 Quinolone antibiotics such as 3-Amino-1-cyclopropyl-6-fluoro-7-(3-hydroxymethyl-pyrrolidin-1-yl)-8-methoxy-1H-quinazoline-2,4-dione, used for treating gramnegative or grampositive bacterial infection in mammals
06/02/2005US20050119230 Pharmaceutical products comprising bisphosphonated
06/02/2005US20050119228 Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
06/02/2005US20050119227 Cyclic amine bace-1 inhibitors having a benzamide substituent
06/02/2005US20050119225 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
06/02/2005US20050119224 Use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for adjuvant treatment of perianal disease
06/02/2005US20050119220 An isolate from the leaves of Gymnema sylvestre obtained by extracting Gymnema sylvestre leaves with aqueous ethanol, removing acid-insoluble salt from the extract, concentrating desalted extract, isolating an insulinotropically active principle
06/02/2005US20050119219 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
06/02/2005US20050119217 Methods and reagents for the treatment of proliferative diseases
06/02/2005US20050119216 Pharmaceutical compositions and methods relating to fucans
06/02/2005US20050119214 Nuclease resistant double-stranded ribonucleic acid
06/02/2005US20050119213 Vascular therapeutics
06/02/2005US20050119210 Using genes encoding transmembrane protein as markers; targets for cancer therapy; drug screening
06/02/2005US20050119206 Cg8327, cg10823, cg18418, cg15862, cg3768, cg11447 and cg16750 homologous proteins involved in the regulation of energy homeostasis
06/02/2005US20050119202 Medicament to treat a fibrotic disease
06/02/2005US20050119201 Inhibitor of dna methylation
06/02/2005US20050119200 Nucleoside derivatives for treating hepatitis C virus infection
06/02/2005US20050119199 Using astaxanthin; tablet or enteric coated capsules
06/02/2005US20050119197 Controlling intracellular concentration; antiproliferative agents; autoimmune diseases;
06/02/2005US20050119196 Remedies for lung cancer
1 ... 4668 4669 4670 4671 4672 4673 4674 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 ... 7860